Exelixis | EXEL - PE Price to Earnings


Exelixis reported 602.31 in PE Price to Earnings for its fiscal quarter ending in December of 2025.





Pe Change Date
Acadia Pharmaceuticals 11.61 2.09 Dec/2025
Agios Pharmaceuticals 3.56 0.68 Sep/2025
Akebia Therapeutics 26.5 0.19 Sep/2023
Amgen 25.31 15.82 Dec/2025
AstraZeneca 27.29 5.8 Dec/2025
Bayer 5.93 0.68 Sep/2025
BioMarin Pharmaceutical 19.24 0.21 Dec/2025
Bristol-Myers Squibb 9.28 1.04 Dec/2025
Eisai 26.63 0.46 Dec/2025
Eli Lilly 40.21 9.66 Dec/2025
Esperion Therapeutics 129.79 129 Dec/2024
Exelixis 602.31 586.25 Dec/2025
Genmab 12.75 0.62 Sep/2025
Glaxosmithkline 11.93 6.46 Sep/2025
Incyte 14.84 2.79 Dec/2025
Ionis Pharmaceuticals 396.15 79.28 Sep/2022
Merck 13.92 5.08 Dec/2025
Moderna 27.22 14.51 Jun/2023
Neurocrine Biosciences 835.47 802.2 Dec/2025
Novartis 15.74 0.15 Sep/2025
Pfizer 14.48 5.18 Dec/2025
Puma Biotechnology 13.93 44.88 Jun/2024
Sanofi 15.75 1.53 Dec/2025
Takeda 235.05 184.95 Dec/2025
Xencor 29.92 3.22 Sep/2022